# argenx SE (ARGX)

Source: https://www.quantisnow.com/company/ARGX
Generated: 2026-11-18T09:00:05.395Z

- Ticker: ARGX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2017
- SEC CIK: 0001697862
- Website: argenx.com

## About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

## Latest ARGX news and filings

- 2026-11-09 13:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6780403)
- 2026-11-09 11:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6779891)
- 2026-11-09 06:00 UTC [Mergers & Acquisitions] [argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities](https://www.quantisnow.com/insight/argenx-to-acquire-unnatural-products-inc-adding-peptide-discovery-engine-6779822)
- 2026-11-09 06:00 UTC [Mergers & Acquisitions] [Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines](https://www.quantisnow.com/insight/unnatural-products-to-be-acquired-by-argenx-for-up-to-6779821)
- 2026-11-05 18:10 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-argenx-se-6775468)
- 2026-11-03 06:00 UTC [Conference Announcement] [argenx to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/argenx-to-present-at-upcoming-investor-conferences-6768081)
- 2026-10-22 12:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6754538)
- 2026-10-22 05:00 UTC [Earnings Date] [argenx Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/argenx-reports-third-quarter-2026-financial-results-and-provides-business-6754013)
- 2026-10-19 12:00 UTC [argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026](https://www.quantisnow.com/insight/argenx-to-present-phase-3-alkivia-results-in-autoimmune-myositis-6750092)
- 2026-10-19 12:59 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6749967)
- 2026-10-15 05:00 UTC [Earnings Date] [argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026](https://www.quantisnow.com/insight/argenx-to-report-third-quarter-2026-financial-results-and-business-6747043)
- 2026-10-08 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6740888)
- 2026-10-08 05:00 UTC [argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease](https://www.quantisnow.com/insight/argenx-provides-update-on-phase-3-unity-study-of-efgartigimod-6740775)
- 2026-10-08 05:00 UTC [argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease](https://www.quantisnow.com/insight/argenx-announces-positive-topline-results-from-phase-2-study-of-6740774)
- 2026-09-29 12:38 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6728690)
- 2026-09-29 12:00 UTC [argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline](https://www.quantisnow.com/insight/argenx-presents-new-data-at-aanem-and-mgfa-scientific-session-6728426)
- 2026-09-17 20:02 UTC [Leadership Update] [argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors](https://www.quantisnow.com/insight/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders-and-6718993)
- 2026-09-01 05:00 UTC [Conference Announcement] [argenx to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/argenx-to-present-at-upcoming-investor-conferences-6700292)
- 2026-08-27 20:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6697228)
- 2026-08-27 13:27 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by argenx SE](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-argenx-se-6696685)
- 2026-08-27 12:50 UTC [Mergers & Acquisitions] [argenx Completes Acquisition of Forte Biosciences, Inc.](https://www.quantisnow.com/insight/argenx-completes-acquisition-of-forte-biosciences-inc-6696601)
- 2026-08-26 12:20 UTC [Analyst Upgrade] [argenx upgraded by UBS with a new price target](https://www.quantisnow.com/insight/argenx-upgraded-by-ubs-with-a-new-price-target-6695050)
- 2026-08-24 14:18 UTC [Analyst Downgrade] [argenx downgraded by Deutsche Bank](https://www.quantisnow.com/insight/argenx-downgraded-by-deutsche-bank-6692372)
- 2026-08-19 11:48 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by argenx SE](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-argenx-se-6687777)
- 2026-08-17 12:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6684500)
- 2026-08-17 10:00 UTC [Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis](https://www.quantisnow.com/insight/zai-lab-and-argenx-announce-positive-topline-results-from-phase-6684021)
- 2026-08-17 05:00 UTC [Earnings Date] [argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis](https://www.quantisnow.com/insight/argenx-announces-positive-topline-results-from-phase-3-alkivia-trial-6683996)
- 2026-08-06 12:05 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by argenx SE](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-argenx-se-6667527)
- 2026-08-06 11:48 UTC [argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.](https://www.quantisnow.com/insight/argenx-announces-commencement-of-tender-offer-to-acquire-forte-biosciences-6667362)
- 2026-08-06 11:06 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by argenx SE](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-argenx-se-6667192)
- 2026-08-04 17:08 UTC [Analyst Coverage Resumed] [Guggenheim resumed coverage on argenx with a new price target](https://www.quantisnow.com/insight/guggenheim-resumed-coverage-on-argenx-with-a-new-price-target-6661658)
- 2026-08-03 20:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6659786)
- 2026-08-03 20:01 UTC [argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026](https://www.quantisnow.com/insight/argenx-announces-extraordinary-general-meeting-of-shareholders-on-september-17-6659514)
- 2026-07-28 21:05 UTC [SEC Form SC TO-C filed by argenx SE](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-argenx-se-6652084)
- 2026-07-27 21:10 UTC [SEC Form SC TO-C filed by argenx SE](https://www.quantisnow.com/insight/sec-form-sc-to-c-filed-by-argenx-se-6650118)
- 2026-07-27 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6648840)
- 2026-07-27 05:07 UTC [Earnings Date] [argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline](https://www.quantisnow.com/insight/argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibody-6648781)
- 2026-07-27 05:00 UTC [Earnings Date] [argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline](https://www.quantisnow.com/insight/argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibody-6648780)
- 2026-07-23 12:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by argenx SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-argenx-se-6646398)
- 2026-07-23 05:00 UTC [Earnings Date] [argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update](https://www.quantisnow.com/insight/argenx-reports-half-year-2026-financial-results-and-provides-second-6645893)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ARGX
- Earnings history: https://www.quantisnow.com/earnings/ARGX
- Dividend history: https://www.quantisnow.com/dividends/ARGX
- Insider transactions: https://www.quantisnow.com/insiders/ARGX
- Options chain: https://www.quantisnow.com/options/ARGX
- SEC 8-K filings only: https://www.quantisnow.com/company/ARGX/8-k
- RSS and alerts for ARGX: https://www.quantisnow.com/docs/rss-feeds.md
